Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.53 |
| ▸ | CA2 | P00918 | 4/20 | 0.53 |
| ▸ | CA12 | O43570 | 3/20 | 0.53 |
| ▸ | CA9 | Q16790 | 3/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.53 |
| ▸ | CA7 | P43166 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4333209 | 0.84 | CA1 (0.57) | CA1CA2CA12CA9CA14 | |
| SCHEMBL13876418 | 0.84 | CA1 (0.57) | CA1CA2CA12CA9CA14 | |
| SCHEMBL1516780 | 0.84 | CA1 (0.57) | CA1CA2CA12CA9CA14 | |
| SCHEMBL28599280 | 0.84 | CA1 (0.57) | CA1CA2CA12CA9CA14 | |
| SCHEMBL7680553 | 0.84 | TSHR (0.50) | CA1CA2CA12CA9CA14 | |
| SCHEMBL10159979 | 0.82 | CA1 (0.55) | CA1CA2CA12CA9CA14 | |
| SCHEMBL20371005 | 0.82 | CA1 (0.55) | CA1CA2CA12CA9CA14 | |
| SCHEMBL14966831 | 0.82 | CA1 (0.55) | CA1CA2CA12CA9CA14 | |
| SCHEMBL84424 | 0.82 | CA1 (0.59) | CA1CA2CA12CA9CA14 | |
| SCHEMBL4408604 | 0.82 | CA1 (0.66) | CA1CA2CA12CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12358881-B2 | Processes for producing amide compounds, and their crystalline and salt form | ALPHALA CO., LTD. (TW) | 2025-07-15 | — | — | US | disclosed |
| WO-2025059562-A1 | SUBSTITUTED AMINOPYRIDINE COMPOUNDS AND METHODS OF TREATING DISEASE USING SAME | ATAVISTIK BIO, INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| CN-117800904-A | ROR gamma inhibitors containing sulfonyl structures | 正大天晴药业集团股份有限公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-113166061-B | ROR gamma inhibitors containing sulfonyl structures | 正大天晴药业集团股份有限公司 | 2023-11-21 | — | — | CN | disclosed |
| US-20230131180-A1 | Processes for producing amide compounds, and their crystalline and salt form | ALPHALA CO., LTD. (TW) | 2023-04-27 | — | — | US | disclosed |
| US-20230131180-A1 | Processes for producing amide compounds, and their crystalline and salt form | ALPHALA CO., LTD. (TW) | 2023-04-27 | — | — | US | disclosed |
| US-20230131180-A1 | Processes for producing amide compounds, and their crystalline and salt form | ALPHALA CO., LTD. (TW) | 2023-04-27 | — | — | US | disclosed |
| EP-4114823-A1 | PROCESSES FOR PRODUCING AMIDE COMPOUNDS, AND THEIR CRYSTALLINE AND SALT FORM | Alphala Co., Ltd. (TW) | 2023-01-11 | — | — | EP | disclosed |
| CN-115052855-A | Preparation method of amide compound, crystal form and salt thereof | 昊运股份有限公司 | 2022-09-13 | — | — | CN | disclosed |
| EP-3573611-B1 | AMIDE COMPOUNDS AND USE THEREOF | ALPHALA CO LTD (TW) | 2022-01-12 | — | — | EP | disclosed |
| EP-1758853-B1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2010-01-20 | — | — | EP | disclosed |
| US-20090156655-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY | 2009-06-18 | — | — | US | disclosed |
| EP-1957068-A2 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | Eli Lilly & Company (US) | 2008-08-20 | — | — | EP | disclosed |
| US-20070249688-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | ELI LILLY AND COMPANY (US) | 2007-10-25 | — | — | US | disclosed |
| US-20070249688-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | ELI LILLY AND COMPANY (US) | 2007-10-25 | — | — | US | disclosed |
| US-20070249688-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | ELI LILLY AND COMPANY (US) | 2007-10-25 | — | — | US | disclosed |
| WO-2007120270-A2 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-10-25 | — | — | WO | disclosed |
| EP-1758853-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005123668-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2005-12-29 | — | — | WO | disclosed |
| WO-2005123668-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156655-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | GLP1R, GCGR, GIPR | CA1 3814/4885CA2 2018/4885CA12 3603/4885 |
| US-12358881-B2 | Processes for producing amide compounds, and their crystalline and salt form | ACMSD, REN, H1-4 | CA1 83/4885CA2 89/4885CA12 250/4885 |
| US-20230131180-A1 | Processes for producing amide compounds, and their crystalline and salt form | ACMSD, REN, H1-4 | CA1 83/4885CA2 89/4885CA12 250/4885 |
| US-20070249688-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | GLP1R, GCGR, GIPR | CA1 4194/4885CA2 2157/4885CA12 3776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.